ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1852

Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study

Katelynn Wilton1, Floranne C. Ernste2, Cynthia S. Crowson3, Eric L. Matteson4, Hilal Maradit Kremers5 and Marta Sánchez-Menéndez6, 1Medical Scientist Training Program, Mayo Clinic Rochester, Rochester, MN, 2Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN, 5Health Sciences Research, Mayo Clinic, Rochester, MN, 6Centro Medico de Asturias, Oviedo, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Cerebrovascular disease, Clinical practice, Clinical research and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis III - Clinical Aspects Psoriatic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients diagnosed with rheumatoid arthritis and psoriatic arthritis (PsA) have an increased risk of multiple comorbidities that predispose them to cardiovascular disease (CVD). Although it has been documented that the Framingham Risk Score (FRS) underestimates the 10-year risk of CVD in patients with rheumatoid arthritis, the predictive accuracy of the FRS has not been evaluated in PsA. 

Methods: The study population comprised a population-based inception cohort of patients with PsA who fulfilled the ClASsification of Psoriatic ARthritis (CASPAR) criteria between 1989 and 2008. Data on CVD risk factors and  all CVD events (myocardial infarction, CV death, angina, revascularization procedures, heart failure, stroke and intermittent claudication) were collected via medical record review. For each patient, the 10 year FRS (Circulation 2008;117;743-753) was calculated at time of PsA diagnosis. Poisson regression models were used to obtain the standardized incidence ratio (SIR), which is the ratio of observed CVD in PsA to predicted CVD obtained from the FRS.

Results: Among 150 incident PsA patients without a history of CVD, 32 patients experienced a CVD event during a mean follow-up of 11.6 years corresponding to an absolute risk of 17.4 per 1000 person years. Of 126 patients who were ≥30 years of age and without a history of CVD at time of PsA diagnosis, the mean FRS was 9.7%. Accounting for length of follow-up, this translated to 10 predicted events. However, 18 patients experienced a CVD event in the first 10 years, corresponding to a 10 year cumulative incidence of 17% (95 % confidence interval [CI]: 10-24%). This was almost twice as high as predicted by the FRS (SIR: 1.80; 95% CI: 1.14-2.86; p=0.012). This two-fold increased CVD risk was consistent across age groups.

Conclusion: We observed a higher than expected incidence of CVD events within our inception cohort of patients with PsA, with an actual risk of about twice that predicted by the FRS. This increased risk underscores the need for close cardiovascular follow-up in this population.


Disclosure:

K. Wilton,
None;

F. C. Ernste,
None;

C. S. Crowson,
None;

E. L. Matteson,
None;

H. Maradit Kremers,

Amgen,

9;

M. Sánchez-Menéndez,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-cardiovascular-risk-in-patients-recently-diagnosed-with-psoriatic-arthritis-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology